Cerity Partners
CYTK icon

Cerity Partners’s Cytokinetics CYTK Stock Holding History

Cerity Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
18,700
+12,652
+209% +$908K ﹤0.01% 1717
2026
Q1 		$399K Sell
6,048
-826
-12% -$52.5K ﹤0.01% 2421
2025
Q4 		$437K Buy
+6,874
New +$428K ﹤0.01% 2193
2025
Q1 		– Sell
-4,066
Closed -$209K – 2508
2024
Q4 		$209K Sell
4,066
-1,080
-21% -$56.1K ﹤0.01% 2217
2024
Q3 		$272K Buy
+5,146
New +$287K ﹤0.01% 2125
2024
Q2 		– Sell
-7,465
Closed -$523K – 2274
2024
Q1 		$523K Buy
+7,465
New +$577K ﹤0.01% 1577

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's CYTK Position: Q2 2026 in Review

Cerity Partners increased its Cytokinetics (CYTK) stake by 209% in Q2 2026, buying an estimated $908K and bringing the position to 18,700 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

Cerity Partners first reported a position in CYTK in Q1 2024 and has held it in 6 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Cerity Partners held 18,700 shares of Cytokinetics worth $1.59M as of Q2 2026.
  • Cerity Partners bought 12,652 Cytokinetics shares in Q2 2026, an estimated $908K.
  • Cytokinetics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1717 holding.
  • Cerity Partners first reported a position in Cytokinetics in Q1 2024 and has held it in 6 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.